No Data
No Data
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
LifeSci Capital analyst Sam Slutsky maintains $Spyre Therapeutics(SYRE.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 47.4%
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody...
Spyre Therapeutics Announces Updated Share Structure
Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody...
On May 14, 2024, Paragon Therapeutics Announced A License Agreement Granting Spyre Therapeutics An Exclusive License To Certain Antibodies And Products Targeting Α4SS7 Integrin And Tl1A, Paragon Will Up To $22M In Milestone Payments-8K
Paragon will provide the Company with an exclusive license to its patents covering the related antibody, the method of use and its method of manufacture.Paragon will not conduct any new campaigns that
Spyre Therapeutics Expands Portfolio and Strengthens Leadership